Sign in
Enrolling by invitationPhase 2

A Global Phase 2 Extension Study of Brogidirsen in Boys With Duchenne Muscular Dystrophy

Key facts

Who runs it
NS Pharma, Inc.
Where
Aurora, Cincinnati, and Richmond, United StatesSee the 3 sitesAlso in 6 other countries, 14 sites
Trial code
Status
Enrolling by invitation
Phase
Phase 2
People taking part
20 people, planned
Starts
16 Dec 2026
Expected to end
3 Sept 2029
Type of study
Interventional
Treatments tested
  • Brogidirsen
Record updated
17 November 2026

Who can take part

Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Participant has successfully completed Study NS-089/NCNP-02-201
  • Participant and parent(s) or legal guardian(s) are willing and able to comply with scheduled visits, investigational product (IP) administration plan, and study procedures
  • Participant must be on a stable dose of glucocorticoid (GC) steroids and is expected to remain on a stable dose of GC steroid treatment for the duration of the study
  • Other inclusion criteria may apply

Who cannot take part

  • Participant is currently taking other investigational drug(s)
  • Participant had an adverse event (AE) in Study NS-089/NCNP-02-201 that, in the judgment of the investigator and/or sponsor, precludes safe use of brogidirsen for the participant in this study
  • Participant had a treatment other than brogidirsen which was made for the purpose of dystrophin or dystrophin-related protein induction after completion of Study NS-089/NCNP-02-201
  • Participant is judged by the investigator to be inappropriate for this study for other reasons
  • Other exclusion criteria may apply

Where in United States

Also in 6 other countries, 14 sites

  • Children's Hospital ColoradoAurora, United StatesEnrolling by invitation
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesEnrolling by invitation
  • Virginia Commonwealth University Health SystemRichmond, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

This Phase 2, open-label, multi-center extension study will be conducted in boys with DMD who completed the 24-week Treatment Period of Study NS-089/NCNP-02-201. Brogidirsen will be administered by IV infusion once weekly for up to 120 weeks (up to a total of 144 weeks of treatment, including weekly dosing from Part 2 of Study NS-089/NCNP-02-201) or until brogidirsen is commercially available, whichever is earlier.

The group in the trial

  • BrogidirsenTreatment being tested

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2 Open-Label Extension Study to Assess the Safety and Efficacy of Brogidirsen in Boys With Duchenne Muscular Dystrophy (DMD)
Record updated
17 November 2026